



PRP ADVISORY

Presence of Flubromazolam (primary) and Caffeine (co-occurring) found in recent Regina Police seizure

February 7, 2022

IMPORTANT

The CPSS has been notified by *Health Canada's* Drug Analysis Service that a benzodiazepine, known as **Flubromazolam** (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) which is controlled under the Controlled Drug and Substances Act (Schedule IV, Item 18), was present in a whitish powder. A secondary/co-occurring substance was also detected in the sample: Caffeine. The substance was received in *Health Canada* laboratory on January 4, 2022, and is the first detection of a substance of concern in the Regina area.

- The substance may also represent a threat to anyone handling it without taking the appropriate health and safety precautions.
- The Drug Analysis Service has instituted a policy to communicate advisories to clients as well as provincial and territorial public health authorities regarding potentially problematic substances. This policy aims to provide information, as part of an early warning system, to warn Canadians of new substances which may pose a potential health hazard.

QUESTIONS:

For more information, write to the **Prescription Review Program** at prp@cps.sk.ca or call 1-306-244-7355.